HMO Melanoma Survivor Stewart Greenberg
Stewart Greenberg – lawyer, husband, grandfather -- was diagnosed with stage four melanoma in 2012. Now cancer-free, Stewart wants the world to know that the Hadassah Medical is changing the way we fight cancer. Hear his story
The Hadassah Melanoma and Cancer Immunotherapy Center (HMCIC), headed by Prof. Michal Lotem, offers several treatments—unique in the world—aimed at strengthening the patient’s immune response to a tumor. Treatments are designed for at stage III and IV patients who have undergone surgery for metastases. Over 200 patients with metastatic melanoma (melanoma that has spread) have been successfully treated over the past 16 years in the Center.
The MHCIC offers two vaccine immunotherapies:
- Autologous Vaccine, prepared with cells from the patient’s own tumor
- Allogeneic Vaccine, engineered to stimulate a more powerful immune response and prepared from a tumor cell line generated at the Center
The vaccination protocol can be used for other cancers besides melanoma, including cancer of the colon, prostate, ovary, lung, and kidney.
Melanoma Research Alliance, Washington, DC National Cancer Institute, Bethesda, MD
The HMCIC often takes part in clinical trials sponsored by pharmaceutical companies developing new drugs for the treatment of metastatic melanoma. The HMCIC also has several active research programs aimed at enhancing the efficacy of melanoma immunotherapy. One of these includes a adoptive cell therapy, where lymphocytes—a type of white blood cells that can kill cancer cells—are extracted from a melanoma tumor, multiplied in the laboratory, and then returned to the patient.
Worldwide, medical research disproportionately focuses on men – leading to misdiagnosis and compromised care for women. Join Hadassah and advocate for gender equity in medical research (GEM). Learn more at hadassah.org/GEM